Affiliation:
1. Department of Pediatrics MedStar Georgetown University Hospital Washington District of Columbia USA
2. Department of Clinical Nutrition Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
3. Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital Washington District of Columbia USA
4. Georgetown University School of Medicine Washington District of Columbia USA
5. Department of Pharmacy MedStar Georgetown University Hospital Washington District of Columbia USA
Abstract
AbstractObjectivesTo review recent evaluations of pediatric patients with intestinal failure (IF) for intestinal transplantation (ITx), waiting list decisions, and outcomes of patients listed and not listed for ITx at our center.MethodsRetrospective chart review of 97 patients evaluated for ITx from January 2014 to December 2021 including data from referring institutions and protocol laboratory testing, body imaging, endoscopy, and liver biopsy in selected cases. Survival analysis used Kaplan–Meier estimates and Cox proportional hazards regression.ResultsPatients were referred almost entirely from outside institutions, one‐third because of intestinal failure‐associated liver disease (IFALD), two‐thirds because of repeated infective and non‐IFALD complications under minimally successful intestinal rehabilitation, and a single patient because of lost central vein access. The majority had short bowel syndrome (SBS). Waiting list placement was offered to 67 (69%) patients, 40 of whom for IFALD. The IFALD group was generally younger and more likely to have SBS, have received more parenteral nutrition, have demonstrated more evidence of chronic inflammation and have inferior kidney function compared to those offered ITx for non‐IFALD complications and those not listed. ITx was performed in 53 patients. Superior postevaluation survival was independently associated with higher serum creatinine (hazard ratio [HR] 15.410, p = 014), whereas inferior postevaluation survival was associated with ITx (HR 0.515, p = 0.035) and higher serum fibrinogen (HR 0.994, p = 0.005).ConclusionsDespite recent improvements in IF management, IFALD remains a prominent reason for ITx referral. Complications of IF inherent to ITx candidacy influence postevaluation and post‐ITx survival.